Hopkins Study finds Weight Loss by Bariatric Embolization Principally from Fatty Tissues

The data from this preliminary study represents a healthy pattern of weight loss in support of bariatric embolization as a valid therapeutic for obesity.

WeightControl.com:   What are the main findings?

Response: In our study, six months after Bariatric Embolization, we found that patients had average reductions in visceral fat of 14%, and in subcutaneous fat of 12%. Additionally, thigh muscle volumes decreased by only 4%. The average liver fat content decreased by 28% and intra-muscular fat decreased by 3 %.

The weight-to-muscle ratio, an indicator of total body weight lost relative to muscle mass, decreased by 5%. Their body fat ratio, a measure of the amount of fatty tissue relative to lean muscle, decreased by 3%.  For patients who are losing weight, a decrease in this ratio indicates a larger loss of fat than muscle. In sum, the weight lost by Bariatric Embolization patients was principally from fatty tissues and overall tended to preserve muscle tissue. In other words, a healthy pattern of weight loss.

WeightControl.com: What should readers take away from your report?

Response: The data from this preliminary study represents a healthy pattern of weight loss in support of bariatric embolization as a valid therapeutic for obesity.

WeightControl.com: What recommendations do you have for future research as a result of this work?

Response: Further research is required to understand exactly how Bariatric Embolization weight loss compares head-to-head with other existing therapies. Given the dramatic decreases in liver fat measured here, future studies may elucidate if Bariatric Embolization can be used to treat existing fatty liver disease.  Additionally, primary care physicians and weight-loss specialists should learn about this procedure, starting with this paper by Hafezi et al which is a systematic review and meta-analysis of the studies performed to date on Bariatric Embolization. This way, they may offer information about Bariatric Embolization to their patients as another tool available to them to treat obesity.


Boston Scientific Co. provided material support and funding support. Siemens Healthcare provided funding support. We also received grant support from the NIH/National Institute of Biomedical Imaging and Bioengineering (NIH-NIBIB-T32).


Abstract No. 166 â–ª FEATURED ABSTRACT

Presented 2023 https://www.sirweb.org/

Bariatric Arterial Embolization is Associated with Significant Muscle-Sparing Weight Loss Detected by Whole-Body Magnetic Resonance Imaging Anthropometry
Herrera, D. Giraldo et al.
Journal of Vascular and Interventional Radiology, Volume 34, Issue 3, S77

The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on March 13, 2023 by weightcontrol